Test af den potentielle metaboliske virkning af det humane tarmbakteriepeptid, Rucilp, hos raske mænd
The goal of this randomized, double-blinded and placebo-controlled clinical cross-over trial is in healthy men to explore the potential metabolic effects of the naturally occurring gut bacterial polypeptide, RUCILP. This bacterial peptide is produced by commensal strains of Ruminococcus torques in the human gut microbiota.
In preclinical studies of rodents, RUCILP lowers blood glucose and stimulates release of plasma insulin, glucagon-like peptide-1(GLP-1) and Peptide YY (PYY) but induces a decline of glucose-dependent insulinotropic polypeptide (GIP).
In the present trial, the investigators want to explore potential effects of intraduodenally delivered RUCILP on release of plasma concentrations of GLP-1, GIP and PYY.
In addition, the investigators will test for potential effects of intestinal RUCILP infusion on plasma concentrations of glucose, insulin and metabolome.
Participants will have a duodenal tube placed into which RUCILP or placebo will be infused over 3 hours after an initial standardized liquid meal infusion into the duodenal tube.
Participants will on different days and in a randomized order receive either placebo or RUCILP infusion into the tube.
Safety is acutely monitored under the intervention and postintervention safety is monitored by clinical biochemistry measures of hematology, and liver and kidney functions. The study participants will further keep a diary of any experienced adverse effects during the week after the intervention.
Primary OUTCOMES: a composite of changes in plasma concentrations of GLP-1, GIP and PYY.
Secondary OUTCOMES: changes in plasma glucose, plasma insulin and plasma metabolome profile.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Hellerup, Danmark, 2900
- Gentofte Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age between 18 and 35 years
- Self-reported good health
- Caucasian
- Normal body mass index (18.5 to <25)
Exclusion Criteria:
- Any known disorder/disease that could interfere with study results or is seen as compromising to the study (as assessed by the investigator), for example diabetes, cancer or cardiovascular or kidney disease.
- Use of any daily medication as well as p.r.n. (pro re nata; not taken regularly) medication that cannot be discontinued during the trial
- Use of antibiotics during the recent three months
- Acute or chronic gastrointestinal symptoms
- Lactose intolerance
- Smoking
- Alcohol or drug abuse
- Use of creatine as dietary supplement during study period
- Plasma creatinine concentration above the normal range (>105 μmol/L)
- Known significant liver disease or plasma ALAT concentration ≥ 3 × normal value
- Values for hemoglobin, leukocytes, or thrombocytes outside of the normal ranges
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Placebo comparator that is identical to the active arm except for the absence of RUCILP |
Placebo is identical to the active intervention except for the absence of the RUCILP molecule. |
|
Aktiv komparator: Active
Intervention is identical to the placebo arm except for the addition of RUCILP to the infusion. |
The naturally occuring gut peptide RUCILP synthesized by the commensal gut bacterium Ruminococcus torques |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma concentrations of GIP
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma measurements of GIP at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
|
Plasma concentrations of GLP-1
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma measurements of GLP-1 at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
|
Plasma concentrations of PYY
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma measurements of PYY at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma concentrations of insulin
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma measurements of insulin at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
|
Plasma concentrations of glucose
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma measurements of glucose at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
|
Plasma metabolome profile
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma metabolome profile at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
|
Plasma concentrations of RUCILP
Tidsramme: During the 3 hours of RUCILP/placebo infusion
|
Plasma measurements of RUCILP at different time points during the study day. |
During the 3 hours of RUCILP/placebo infusion
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Estimeret glomerulær filtreringshastighed (EGFR)
Tidsramme: Ved baseline, 180 minutter og ved opfølgning (4-8 dage efter studiedagen)
|
Ved baseline, 180 minutter og ved opfølgning (4-8 dage efter studiedagen)
|
|
|
Blood leukocytes
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of leukocytes in blood |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Blood eosinophils
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of eosinophils in blood |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Total blood leukocytes
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of total leukocytes in blood |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Blood neutrophils
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of neutrophils in blood |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Blood platelets
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of platelets in blood |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Blood hemoglobin
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of hemoglobin in blood |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma alanine transaminase (ALT)
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of alanine transaminase (ALT) in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma aspartate transferase (AST)
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of aspartate transferase (AST) in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma alkaline phosphatase
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of alkaline phosphatase in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma albumin
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of albumin in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma creatinine
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of creatinine in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma sodium
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of sodium in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma potassium
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of potassium in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma calcium (total)
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of total calcium in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma phosphate
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of phosphate in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma creatine kinase
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of creatine kinase in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Plasma C-reactive protein
Tidsramme: At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
Concentration of C-reactive protein in plasma |
At baseline, at 180 minutes, and at follow-up (4-8 days after study day)
|
|
Experienced adverse effects post infusion
Tidsramme: At 180 minutes.
|
Number of experienced adverse effects as noted in a diary at end of each study day. |
At 180 minutes.
|
|
Experienced adverse effects during the four days following an infusion
Tidsramme: During four days of follow-up after each study day.
|
Number of experienced adverse effects as noted in a diary during four days of follow-up after each infusion. |
During four days of follow-up after each study day.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- H-22011935
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Due to GDPR regulations we are unable to share IPD with other researchers.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .